Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1

Conditions

Thrombocytopenia 1Purpura, Thrombocytopenic, Idiopathic 1Purpura, Thrombocytopenic 1Neoplasms 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × romiplostim × Clear all
NCT00515203 2014-07-25

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Amgen

Phase 1/2 Completed
22 enrolled 13 charts 1 FDA

Purpura, Thrombocytopenic, Purpura, Thrombocytopenic, Idiopathic

NCT00283439 2011-06-20

A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

Amgen

Phase 1/2 Completed
39 enrolled 13 charts
Classical hematologyLymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡